Ravasio, R., Cranmer, H., Kearns , I., Viti, R. and Corinti, S. 2022. Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor. AboutOpen. 9, 1 (Oct. 2022), 92–104. DOI:https://doi.org/10.33393/ao.2022.2450.